| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6199093 | Ophthalmology | 2016 | 10 Pages |
Abstract
Rates of selected ocular and systemic adverse events with IAI were similar to those of controls and similar across disease states in evaluated IAI trials. Intravitreal aflibercept injection was generally well tolerated in the patients evaluated.
Keywords
SAEAPTCBRVOCRVOnAMDIAIHTNDMEPYRATEDiabetic macular edemaBranch retinal vein occlusionCentral retinal vein occlusionSensitivity analysisintravitreal aflibercept injectionneovascular age-related macular degenerationarterial thromboembolic eventSerious adverse eventconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)HypertensionRate Ratio
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
John W. MD, Diana V. MD, David S. MD, Desmond PhD, Andrea PhD, Namrata OD, Robert MD, Alyson J. MD, PhD, Peter K. MD,